ProCE Banner Activity

CME

Individualizing CLL Therapy: Second-Line Treatment and Beyond

Text Module

In this case-focused, text-based activity, experts discuss key factors in selecting treatment for patients with relapsed/refractory chronic lymphocytic leukemia.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: September 16, 2024

Expiration: August 15, 2025

Share

Faculty

Jeremy S Abramson

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Farrukh T. Awan

Farrukh T. Awan, MD, MS, MBA

Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Shuo Ma

Shuo Ma, MD, PhD

Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC in partnership with CLL Society

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc.; AstraZeneca; Beigene, Ltd.; and Bristol Myers Squibb.

AbbVie Inc.

AstraZeneca

BeiGene, Ltd.

Bristol Myers Squibb

Partners

CLL Society

ProCE Banner

Target Audience

This program is intended for patients with chronic lymphocytic leukemia and their caregivers along with hematologists and other healthcare professionals who care for those patients.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Chronic Lymphocytic Leukemia (CLL).

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Select therapy for patients with CLL/SLL, taking into consideration markers of risk and efficacy, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference

  • Describe the varied selectivity, binding, efficacy, and safety of different targeted agents for the treatment of CLL/SLL

  • Select optimal therapy for patients with relapsed/refractory CLL/SLL guided by prior treatment and both patient and disease characteristics

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Cellectar, Foresight Diagnostics, Genentech, Gilead, Incyte, Interius, Janssen, Lilly, Novartis, Roche, Seagen; researcher: Bristol Myers Squibb, Celgene, Cellectics, Genentech, Merck, Mustang Bio, Regeneron, Seagen, Takeda.

Farrukh T. Awan, MD, MS, MBA

Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh T. Awan, MD, MS, MBA: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADCT Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou, Dava Oncology, Genmab, Incyte, Kite, Loxo Oncology; researcher: AbbVie/Pharmacyclics.

Shuo Ma, MD, PhD

Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Shuo Ma, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Lilly, Janssen; researcher: Bristol Myers Squibb.

The planners and content peer reviewers from Clinical Care Options, LLC and CLL Society do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 16, 2024, through August 15, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.